Status:

COMPLETED

The Safety and Dose Response to Single Anal Doses of NRL001

Lead Sponsor:

Norgine

Conditions:

Faecal Incontinence

Eligibility:

All Genders

18-75 years

Phase:

PHASE1

Brief Summary

Single centre dose-finding and proof-of-concept study in healthy volunteers to assess the effects of single doses of NRL001 on the mean anal resting pressure (MARP). In addition, the pharmacokinetics ...

Detailed Description

This is a single centre dose-finding and proof-of-concept study in healthy volunteers to assess the effects of single doses of NRL001 on the mean anal resting pressure (MARP). In addition, the pharmac...

Eligibility Criteria

Inclusion

  • No previous history of ano-rectal conditions/diseases.
  • No history of heart disease.
  • 18 to 75 years of age.
  • Males and females but pre-menopausal females of child bearing potential must be using adequate contraceptive methods and have a negative pregnancy test before the start of the study.

Exclusion

  • Use of medication in the last 30 days with vasodilatory activity.
  • Use of any medication in the last 30 days applied to the anus and/or via the rectum (exception: participation in Part A, Part B or Part C of NRL001-01/2002(HV)
  • Regular intake of more than 21 units of alcohol per week.
  • Pregnant females.
  • Breast feeding mothers.
  • Presence of concomitant gastrointestinal diseases or disorders, such as significant abdominal symptoms and haemorrhoids but also any significant organ (e.g. renal, hepatic or cardiac)dysfunction.
  • Volunteers whom the investigator feels would not be compliant with the requirements of the trial.

Key Trial Info

Start Date :

December 1 2002

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 12 2013

Estimated Enrollment :

44 Patients enrolled

Trial Details

Trial ID

NCT06593743

Start Date

December 1 2002

End Date

November 12 2013

Last Update

September 19 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University Hospital - Queens Medical Centre

Nottingham, United Kingdom, NG7 2UH

The Safety and Dose Response to Single Anal Doses of NRL001 | DecenTrialz